Top

Archives of Gynecology and Obstetrics

Published in:

01-09-2011 | Gynecologic Oncology

Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre

Authors: Nisrin Anfinan, Khalid Sait, Prafull Ghatage, Jill Nation, Pam Chu

Published in: Archives of Gynecology and Obstetrics | Issue 3/2011

Abstract

Objective

The aim of this study was to review the clinical outcomes of patients with borderline ovarian tumors (BOTs) at Tom Baker Cancer Centre (TBCC) and to assess the value of surgical staging.

Methods

This retrospective study included 138 patients treated for BOTs at TBCC between January 1994 and December 2005. Patients were divided into two groups: group I with complete surgical staging (n = 89) and group II with incomplete surgical staging (n = 49). This population-based study identified patients using the Alberta Cancer Registry. Charts were reviewed by a single person. Data extracted included demographic information and prognostic factors such as age, histological type, laterality of the cyst, presence of microinvasion, and the type of surgical procedure. Data were extracted and entered into a study database for analysis. Overall survival and overall recurrence-free survival of both groups were calculated using the Kaplan–Meier method. Risk factors for recurrence were analyzed using Cox regression analysis.

Results

A total of 138 patients were enrolled, with a mean age of 46 years. The median follow-up time was 37 months. The most common histological type of BOT was the serous type found in 70 (50.7%) patients. Microinvasion was identified in four (2.9%) patients. Twelve patients were found to have implants as result of the staging procedure; two of them were invasive implants and both required chemotherapy. Forty-three (31%) patients had conservative surgery and 95 (68.8%) patients had non-conservative surgery. Nine (6.5%) patients experienced recurrence: five (5.6%) patients in group I versus four (8.2%) patients in group II. The presence of microinvasion is the risk factor for recurrence (P = 0.013).

Conclusions

The indications for restaging surgery remain controversial, as there was no difference in recurrence rates observed between the study groups. However, surgical staging is important for identifying invasive extraovarian implants that need to be treated with chemotherapy. For patients who have conservative surgery, close- and long-term follow-up is required.

Gotlieb WH, Flikker S, Davidson B, Korach Y, Kopolovic J, Ben-Baruch G (1998) Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 82:141–146PubMedCrossRef

Kennedy AW, Hart RH (1996) Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): a long term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 78:278–286PubMedCrossRef

Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16:513–527PubMedCrossRef

Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E (2004) Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 100:1145–1151PubMedCrossRef

Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, Kose MF (2005) Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97:845–851PubMedCrossRef

Morice P, Camette S, El Hassan J, Pautier P, Duvillard P, Castaigne D (2001) Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 75:92–96PubMedCrossRef

Ayhan A, Celik H, Taskiran C, Bozdag G, Aksu T (2003) Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 24:223–232PubMed

Scully RE (1982) Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential). Bull Cancer 69:228–238PubMed

International Federation of Gynecology and Obstetrics (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156:263–264

10.

Trope C, Kaern J (1998) Management of borderline tumors of the ovary: state of the art. Semin Oncol 25:372–380PubMed

11.

Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C (1998) Serous borderline tumor of the ovary with noninvasive peritoneal implants. Cancer 83:2157–2163PubMedCrossRef

12.

Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C (1998) Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 82:1096–1103PubMedCrossRef

13.

Leake JF, Currie JL, Rosenshein NB, Woodruff JD (1992) Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 47:150–158PubMedCrossRef

14.

Tazelaar HD, Bostwick DG, Ballon SC, Hendrickson MR, Kempson RL (1985) Conservative treatment of borderline ovarian tumors. Obstet Gynecol 66:417–422PubMed

15.

Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW (1993) Epithelial ovarian tumors of borderline malignancy: long-term follow-up. Gynecol Oncol 50:316–322PubMedCrossRef

16.

Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, Duvillard P, Castaigne D (2004) Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 40:1842–1849PubMedCrossRef

17.

Winter WE 3rd, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL (2002) Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 100:671–676PubMedCrossRef

18.

Trimble CL, Kosary C, Trimble EL (2002) Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86:34–37PubMedCrossRef

19.

Bell DA, Scully RE (1990) Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 21:397–403PubMedCrossRef

20.

Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG (2002) Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 99(1):11–17PubMedCrossRef

21.

Seidman JD, Kurman RJ (2000) Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 31:539–557PubMedCrossRef

Title: Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre
Authors: Nisrin Anfinan
Khalid Sait
Prafull Ghatage
Jill Nation
Pam Chu
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 3/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1713-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

Female plastic and reconstructive surgeons’ personal decision making for breast cancer treatment and reconstruction

Does primary breast cancer in older women (≥80 years) have unfavorable histological characteristics?

Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist

The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study

Serum concentrations of CA-125 in normal and preeclamptic pregnancies

Plasma vitamin C levels and risk of preterm prelabour rupture of membranes